Abstract
Tumor development, growth, and progression depend on some combination of altered cell cycle regulation, excessive growth factor pathway activation, and decreased apoptosis. Understanding the complex molecular mechanisms that underlie these processes should therefore lead to the identification of potential targets for therapeutic intervention. The estrogen receptor and HER-2 / neu were among the earliest targets investigated, ultimately leading to the widespread use of tamoxifen and trastuzumab, respectively, in the treatment of breast cancer. Major research advances have since led to other classes of targeted therapies, including cyclin-dependent kinase inhibitors, histone deactylase inhibitors, and receptor tyrosine kinase inhibitors. The following review provides a discussion of the molecular biology associated with each of these types of therapies as well as a detailed summary of the preclinical and clinical data published on selected compounds from each of these subgroups.
Keywords: Cancer Therapeutics, breast cancer, tamoxifen, trastuzumab, tyrosine kinase
Current Cancer Drug Targets
Title: Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Volume: 4 Issue: 5
Author(s): M. C. Liu, J. L. Marshall and R. G. Pestell
Affiliation:
Keywords: Cancer Therapeutics, breast cancer, tamoxifen, trastuzumab, tyrosine kinase
Abstract: Tumor development, growth, and progression depend on some combination of altered cell cycle regulation, excessive growth factor pathway activation, and decreased apoptosis. Understanding the complex molecular mechanisms that underlie these processes should therefore lead to the identification of potential targets for therapeutic intervention. The estrogen receptor and HER-2 / neu were among the earliest targets investigated, ultimately leading to the widespread use of tamoxifen and trastuzumab, respectively, in the treatment of breast cancer. Major research advances have since led to other classes of targeted therapies, including cyclin-dependent kinase inhibitors, histone deactylase inhibitors, and receptor tyrosine kinase inhibitors. The following review provides a discussion of the molecular biology associated with each of these types of therapies as well as a detailed summary of the preclinical and clinical data published on selected compounds from each of these subgroups.
Export Options
About this article
Cite this article as:
Liu C. M., Marshall L. J. and Pestell G. R., Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation, Current Cancer Drug Targets 2004; 4 (5) . https://dx.doi.org/10.2174/1568009043332907
DOI https://dx.doi.org/10.2174/1568009043332907 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor-Induced Alterations in Lipid Metabolism
Current Medicinal Chemistry Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design An Apple Plus a Brazil Nut a Day Keeps the Doctors Away: Antioxidant Capacity of Foods and their Health Benefits
Current Pharmaceutical Design Effects of Bioactive Peptide on Inflammatory Bowel Disease, Focus on Signal Transduction and Intestinal Microbiota
Current Pharmaceutical Design In Vivo Target Validation: Methodology and Case Studies on the Janus Kinase Tyk2
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry In Vitro and In Vivo Evaluation of [99mTc(CO)3]-Radiolabeled ErbB-2-Targeting Peptides for Breast Carcinoma Imaging
Current Radiopharmaceuticals Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
Recent Patents on Anti-Cancer Drug Discovery Modulating Poly (ADP-Ribose) Polymerase Activity: Potential for the Prevention and Therapy of Pathogenic Situations Involving DNA Damage and Oxidative Stress
Current Pharmaceutical Biotechnology The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Regulation of Angiogenesis by the Kallikrein-Kinin System
Current Pharmaceutical Design Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Drug Resistance: Challenges to Effective Therapy
Current Cancer Drug Targets Copper Complexes of 8-Aminoquinoline and Uracils as Novel Aromatase Inhibitors
Letters in Drug Design & Discovery Experimental Onco-Immunology Revisited
Current Cancer Therapy Reviews Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Development and Validation of Predictive Molecular Signatures
Current Molecular Medicine